002550 千红制药
已收盘 10-23 15:00:00
资讯
新帖
简况
千红制药(002550)披露向不特定对象发行可转换公司债券方案,10月23日股价上涨1.46%
证券之星 · 10-23 18:12
千红制药(002550)披露向不特定对象发行可转换公司债券方案,10月23日股价上涨1.46%
股市必读:千红制药新发布《千红制药:第六届董事会第十五次会议决议公告》
证券之星 · 10-23 03:25
股市必读:千红制药新发布《千红制药:第六届董事会第十五次会议决议公告》
千红制药:拟发行10亿元可转债
每日经济新闻 · 10-22 20:31
千红制药:拟发行10亿元可转债
股市必读:千红制药(002550)10月15日董秘有最新回复
证券之星 · 10-16
股市必读:千红制药(002550)10月15日董秘有最新回复
千红制药:该创新药I类沟通交流会议为公司QHRD211项目
证券之星 · 10-15
千红制药:该创新药I类沟通交流会议为公司QHRD211项目
千红制药:公司可转债项目的发行工作正在积极有序推进中
证券之星 · 10-15
千红制药:公司可转债项目的发行工作正在积极有序推进中
股市必读:千红制药(002550)10月12日董秘有最新回复
证券之星 · 10-13
股市必读:千红制药(002550)10月12日董秘有最新回复
千红制药(002550)9月30日主力资金净买入2562.99万元
证券之星 · 09-30
千红制药(002550)9月30日主力资金净买入2562.99万元
股市必读:千红制药(002550)9月11日董秘有最新回复
证券之星 · 09-14
股市必读:千红制药(002550)9月11日董秘有最新回复
千红制药:公司原创一类新药QHRD106和QHRD107均按预设进度正常推进中
证券之星 · 09-09
千红制药:公司原创一类新药QHRD106和QHRD107均按预设进度正常推进中
千红制药:公司始终以创新驱动发展为核心战略
证券之星 · 08-26
千红制药:公司始终以创新驱动发展为核心战略
东海证券:给予千红制药买入评级
证券之星 · 08-14
东海证券:给予千红制药买入评级
千红制药半年报净利降逾四成,原料药收入“腰斩”拖累业绩,企业回应肝素寒冬下逆势扩产争议
蓝鲸财经 · 08-10
千红制药半年报净利降逾四成,原料药收入“腰斩”拖累业绩,企业回应肝素寒冬下逆势扩产争议
千红制药(002550)6月30日股东户数7.09万户,较上期减少4.88%
证券之星 · 08-08
千红制药(002550)6月30日股东户数7.09万户,较上期减少4.88%
千红制药(002550)披露2025年员工持股计划(草案)摘要(修订稿),8月7日股价上涨2.47%
证券之星 · 08-07
千红制药(002550)披露2025年员工持股计划(草案)摘要(修订稿),8月7日股价上涨2.47%
千红制药(002550.SZ)发布半年度业绩,归母净利润1.53亿元,同比下降40.78%
智通财经 · 08-07
千红制药(002550.SZ)发布半年度业绩,归母净利润1.53亿元,同比下降40.78%
股市必读:千红制药(002550)7月30日董秘有最新回复
证券之星 · 07-31
股市必读:千红制药(002550)7月30日董秘有最新回复
千红制药:公司可转债发行方案将在严格遵循相关证券法规及市场规则的基础上,综合考虑公司及广大投资者的相关权益
证券之星 · 07-30
千红制药:公司可转债发行方案将在严格遵循相关证券法规及市场规则的基础上,综合考虑公司及广大投资者的相关权益
千红制药(002550.SZ)向不特定对象发行可转债申请获中国证监会同意注册批复
智通财经 · 07-16
千红制药(002550.SZ)向不特定对象发行可转债申请获中国证监会同意注册批复
股市必读:千红制药(002550)7月14日董秘有最新回复
证券之星 · 07-15
股市必读:千红制药(002550)7月14日董秘有最新回复
公司概况
公司名称:
常州千红生化制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-18
主营业务:
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是肝素钠系列、依诺肝素系列、达肝素钠系列、那屈肝素钙系列、胰激肽原酶系列、复方消化酶胶囊(II)、门冬酰胺酶系列、弹性酶系列、肠衣系列。公司是国家级高新技术企业,获得了全国总工会授予的“全国五一劳动奖状”以及江苏省总工会授予的“模范职工之家”、“江苏省最美职工之家”称号。
发行价格:
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":6.27,"timestamp":1792739034000,"preClose":6.18,"halted":0,"volume":24225632,"delay":0,"changeRate":0.0146,"floatShares":953999999,"shares":1280000000,"eps":0.2294,"marketStatus":"已收盘","change":0.09,"latestTime":"10-23 15:00:00","open":6.15,"high":6.27,"low":6.01,"amount":149000000,"amplitude":0.0421,"askPrice":6.27,"askSize":648,"bidPrice":6.26,"bidSize":582,"shortable":0,"etf":0,"ttmEps":0.2294,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.18,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":6.8,"lowLimit":5.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":2.89,"roa":"--","peRate":27.332171,"roe":"5.62%","epsLYR":0.32,"committee":-0.438604,"marketValue":8024000000,"turnoverRate":0.0254,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-10-26。","floatMarketCap":5979000000},"requestUrl":"/m/hq/s/002550/wiki","defaultTab":"wiki","newsList":[{"id":"2677592384","title":"千红制药(002550)披露向不特定对象发行可转换公司债券方案,10月23日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677592384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677592384?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:12","pubTimestamp":1792750359,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,千红制药报收于6.27元,较前一交易日上涨1.46%,最新总市值为80.24亿元。该股当日开盘6.15元,最高6.27元,最低6.01元,成交额达1.49亿元,换手率为2.54%。千红制药于近日披露《第六届董事会第十五次会议决议公告》,审议通过《关于进一步明确公司向不特定对象发行可转换公司债券方案的议案》。同时,会议审议通过可转债上市、募集资金专项账户设立等相关议案。本次发行无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300033796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677399552","title":"股市必读:千红制药新发布《千红制药:第六届董事会第十五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677399552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677399552?lang=zh_cn&edition=full","pubTime":"2026-10-23 03:25","pubTimestamp":1792697153,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘,千红制药报收于6.18元,下跌1.44%,换手率0.7%,成交量6.65万手,成交额4139.77万元。公司公告汇总千红制药:第六届董事会第十五次会议决议公告审议通过《关于进一步明确公司向不特定对象发行可转换公司债券方案的议案》,明确发行总额10亿元,每张面值100元,期限6年,初始转股价格6.42元/股,债券评级AA,不提供担保;同时审议通过可转债上市、募集资金专项账户设立等相关议案;本次发行无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300004006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677195963","title":"千红制药:拟发行10亿元可转债","url":"https://stock-news.laohu8.com/highlight/detail?id=2677195963","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677195963?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:31","pubTimestamp":1792672260,"startTime":"0","endTime":"0","summary":"每经AI快讯,10月22日,千红制药公告,公司拟向不特定对象发行可转换公司债券,发行总金额为10亿元,发行数量为1000万张,每张面值100元;申购日为2026年10月27日(T日)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-10-22/doc-iniwchpf5858059.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-10-22/doc-iniwchpf5858059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FCEF","BK0239","SABA","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675378532","title":"股市必读:千红制药(002550)10月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675378532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675378532?lang=zh_cn&edition=full","pubTime":"2026-10-16 02:53","pubTimestamp":1792090387,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘,千红制药报收于6.15元,下跌1.76%,换手率0.97%,成交量9.23万手,成交额5728.48万元。董秘最新回复投资者: 尊敬的董秘:您好!董秘: 尊敬的股东,您好,该创新药I类沟通交流会议为公司QHRD211项目,具体临床进展敬情关注公司后续信披披露相关公告,感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600002559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582062","title":"千红制药:该创新药I类沟通交流会议为公司QHRD211项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582062?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:48","pubTimestamp":1792068502,"startTime":"0","endTime":"0","summary":"证券之星消息,千红制药(002550)10月15日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘:您好!公司2026-09-04的I类沟通交流会议(编号2026006060)已反馈,涉及哪个创新药项目?是否属于突破性治疗相关沟通?千红制药回复:尊敬的股东,您好,该创新药I类沟通交流会议为公司QHRD211项目,具体临床进展敬情关注公司后续信披披露相关公告,感谢您的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500037424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","06978","BK0239","BK1574","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675372447","title":"千红制药:公司可转债项目的发行工作正在积极有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2675372447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675372447?lang=zh_cn&edition=full","pubTime":"2026-10-15 11:33","pubTimestamp":1792035184,"startTime":"0","endTime":"0","summary":"证券之星消息,千红制药(002550)10月15日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,公司的可转债发行已经通过三个月了,公司还在对发行推行迟缓是在准备放弃发行了吗?还是公司在准备想通过其他办法让可转债上市利益最大化?千红制药回复:尊敬的投资者,您好,公司可转债项目的发行工作正在积极有序推进中,不存在放弃发行的情形。具体发行时点请以公司公告为准。感谢您对公司的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500016124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675801098","title":"股市必读:千红制药(002550)10月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675801098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675801098?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:23","pubTimestamp":1791825789,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘,千红制药报收于6.39元,下跌1.99%,换手率0.96%,成交量9.18万手,成交额5904.63万元。董秘最新回复投资者: 尊敬的董秘:您好!中小股东要求提供股东人数的权利被忽视!请及时解决并回复董秘: 尊敬的投资者,您好,公司始终重视与中小股东的沟通交流,并已注意到您反馈的邮箱容量问题。当日关注点交易信息汇总:10月12日主力资金净流出908.39万元,占总成交额15.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827678","title":"千红制药(002550)9月30日主力资金净买入2562.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827678","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671827678?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:27","pubTimestamp":1790753277,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月30日收盘,千红制药报收于6.59元,上涨4.11%,换手率2.9%,成交量27.65万手,成交额1.82亿元。9月30日的资金流向数据方面,主力资金净流入2562.99万元,占总成交额14.09%,游资资金净流出797.52万元,占总成交额4.38%,散户资金净流出1765.48万元,占总成交额9.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667838680","title":"股市必读:千红制药(002550)9月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2667838680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667838680?lang=zh_cn&edition=full","pubTime":"2026-09-14 01:16","pubTimestamp":1789319769,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,千红制药报收于6.31元,下跌4.39%,换手率2.01%,成交量19.13万手,成交额1.22亿元。董秘最新回复投资者: 董秘,您好。截止至2026年8月31号。当日关注点交易信息汇总:9月11日主力资金净流出2283.79万元,占总成交额18.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400000520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666730560","title":"千红制药:公司原创一类新药QHRD106和QHRD107均按预设进度正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730560","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666730560?lang=zh_cn&edition=full","pubTime":"2026-09-09 08:39","pubTimestamp":1788914348,"startTime":"0","endTime":"0","summary":"证券之星消息,千红制药09月08日在投资者关系平台上答复投资者关心的问题。对于创新药管线106和107的进度能否及时公布?公司原创一类新药QHRD106和QHRD107均按预设进度正常推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900007782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662979803","title":"千红制药:公司始终以创新驱动发展为核心战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2662979803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662979803?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:07","pubTimestamp":1787728032,"startTime":"0","endTime":"0","summary":"证券之星消息,千红制药(002550)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问:董事长请请你怎么看待公司上市十多年都没有一个新药注册上市长期靠几个老药支撑?还有作为上市公司为什么在创新药的能做到临床数据信息不透明,进度前后矛盾的呢?千红制药回复:尊敬的投资者,您好,公司始终以创新驱动发展为核心战略,目前多个原创新药正处于科学、有序地推进临床试验进程中,相关进展将严格遵循法规披露要求。公司严格按照证监会和交易所的相关规定履行信息披露义务,不存在应披露未披露的重大事项。感谢您对公司的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600029327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659197160","title":"东海证券:给予千红制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2659197160","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659197160?lang=zh_cn&edition=full","pubTime":"2026-08-14 12:08","pubTimestamp":1786680487,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏近期对千红制药进行研究并发布了研究报告《公司简评报告:制剂业务整体平稳,原料药业务下滑》,给予千红制药买入评级。受肝12.84%素原料药量价齐跌的影响,公司业绩短期放缓。公司致力于打造传统业务全产业链优势,同时积极布局创新业务,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,增持评级1家。本文数据来源于东海证券股份有限公司,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400017069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658984318","title":"千红制药半年报净利降逾四成,原料药收入“腰斩”拖累业绩,企业回应肝素寒冬下逆势扩产争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658984318","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658984318?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:18","pubTimestamp":1786353534,"startTime":"0","endTime":"0","summary":"对于上半年业绩下滑的原因,千红制药在半年报中解释称,由于全球肝素原料药行业持续低迷的市场需求以及全球高压态势下严峻的医药生态环境,出现了肝素原料药产品集体量价齐降的情况,导致海外销售持续下降。千红制药财报中显示,肝素原料药是从健康生猪的小肠粘膜中提取的肝素粗品经进一步提纯后而制成的特色原料药。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786353483569331364","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657002627","title":"千红制药(002550)6月30日股东户数7.09万户,较上期减少4.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657002627","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657002627?lang=zh_cn&edition=full","pubTime":"2026-08-08 17:03","pubTimestamp":1786179812,"startTime":"0","endTime":"0","summary":"证券之星消息,近日千红制药披露,截至2026年6月30日公司股东户数为7.09万户,较3月31日减少3634.0户,减幅为4.88%。在化学制药行业个股中,千红制药股东户数高于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.59万户。从股价来看,2026年3月31日至2026年6月30日,千红制药区间跌幅为16.73%,在此期间股东户数减少3634.0户,减幅为4.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800012855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657428246","title":"千红制药(002550)披露2025年员工持股计划(草案)摘要(修订稿),8月7日股价上涨2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657428246","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657428246?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:41","pubTimestamp":1786113674,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,千红制药报收于7.04元,较前一交易日上涨2.47%,最新总市值为90.1亿元。该股当日开盘6.81元,最高7.06元,最低6.8元,成交额达1.95亿元,换手率为2.94%。近日,千红制药发布《2025年员工持股计划(草案)摘要(修订稿)》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161968","title":"千红制药(002550.SZ)发布半年度业绩,归母净利润1.53亿元,同比下降40.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161968?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:08","pubTimestamp":1786093712,"startTime":"0","endTime":"0","summary":"智通财经APP讯,千红制药(002550.SZ)披露2026年半年度报告,报告期公司实现营收7.58亿元,同比下降12%;归属于上市公司股东的净利润1.53亿元,同比下降40.78%;扣非净利润1.42亿元,同比下降28.46%;基本每股收益0.1215元。业绩变动主要原因是由于全球肝素原料药行业持续低迷的市场需求,以及全球高压态势下严峻的医药生态环境,出现了肝素原料药产品集体量价齐降的情况,导致海外销售出现持续下降的结果。国内市场销售虽受集采降价影响,但得益于多年的技术质量进步及品牌影响力,主要产品销售数量及市场占有率持续提升,基本态势持续向好,而海外市场整体销售业绩预计在下半年趋稳向好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655110800","title":"股市必读:千红制药(002550)7月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655110800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655110800?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:42","pubTimestamp":1785436934,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘,千红制药报收于6.78元,下跌1.17%,换手率1.58%,成交量14.88万手,成交额1.01亿元。董秘最新回复投资者: 董秘您好:公司可转债发行能否考虑中小股东切身利益,维护二级市场股价入手,提高转股价格,不要稀释每股收益!!!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655841022","title":"千红制药:公司可转债发行方案将在严格遵循相关证券法规及市场规则的基础上,综合考虑公司及广大投资者的相关权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2655841022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655841022?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:37","pubTimestamp":1785382665,"startTime":"0","endTime":"0","summary":"证券之星消息,千红制药(002550)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:公司可转债发行能否考虑中小股东切身利益,维护二级市场股价入手,提高转股价格,不要稀释每股收益!!!千红制药回复:尊敬的投资者,您好,公司可转债发行方案将在严格遵循相关证券法规及市场规则的基础上,综合考虑公司及广大投资者的相关权益,感谢您对公司的关注与支持。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000015001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486744","title":"千红制药(002550.SZ)向不特定对象发行可转债申请获中国证监会同意注册批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486744","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651486744?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:37","pubTimestamp":1784194668,"startTime":"0","endTime":"0","summary":"智通财经APP讯,千红制药(002550.SZ)发布公告,公司于近日收到中国证券监督管理委员会出具的《关于同意常州千红生化制药股份有限公司向不特定对象发行可转换公司债券注册的批复》,同意公司向不特定对象发行可转换公司债券的注册申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FCEF","SABA","BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651483088","title":"股市必读:千红制药(002550)7月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651483088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651483088?lang=zh_cn&edition=full","pubTime":"2026-07-15 02:16","pubTimestamp":1784052971,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘,千红制药报收于7.02元,上涨1.15%,换手率4.06%,成交量38.23万手,成交额2.65亿元。董秘最新回复投资者: 董秘请问:你说公司十分重视公司的市值,那么请问公司有没有制定上市公司的《市值管理的制度》呢?当日关注点交易信息汇总:7月14日主力资金净流入584.69万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500002558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792847354392,"stockEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":-0.0398},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.1204},{"period":"1year","weight":-0.2761},{"period":"ytd","weight":-0.1831}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"70890人(较上一季度减少4.88%)","perCapita":"13451股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是肝素钠系列、依诺肝素系列、达肝素钠系列、那屈肝素钙系列、胰激肽原酶系列、复方消化酶胶囊(II)、门冬酰胺酶系列、弹性酶系列、肠衣系列。公司是国家级高新技术企业,获得了全国总工会授予的“全国五一劳动奖状”以及江苏省总工会授予的“模范职工之家”、“江苏省最美职工之家”称号。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}